Monitor for continued insider selling in the next 30 days; isolated transactions at this level are routine, but a pattern could signal reduced confidence. The non-cash grants are standard compensation and not actionable.
MDGL drugs
MDGL drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 3 $425.85entry
- T+1 · 9mo ago +2.10%α +1.40% · $434.80
- T+5 · 8mo ago +1.63%α +2.09% · $432.78
- T+20 · 8mo ago +22.92%α +27.33% · $523.47
- T+60 · 6mo ago +21.16%α +10.24% · $515.96
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Seven insiders at Madrigal Pharmaceuticals, including the CEO, CFO, and other C-suite executives, conducted open-market sales and stock awards within a 7-day window. The total value of open-market sales was approximately $2.37 million, representing modest insider selling activity at a company with a $10.1 billion market cap.
Key Financial Metrics
Key Facts
- CEO William Sibold sold $718,316 worth of shares in open-market transactions on March 6, 2026.
- CFO Mardi Dier sold $505,389 worth of shares on March 2, 2026.
- Four other C-suite executives sold shares totaling $1.15 million on March 6.
- Five insiders received non-cash stock awards totaling 27,375 shares on March 4, 2026.
- Total open-market selling amounted to $2.37 million over 7 days.
- Selling represents ~0.023% of the company's $10.1 billion market capitalization.
Financial Impact
$2.37 million in open-market insider sales over 7 days, representing 0.023% of market cap
Risk Factors
- Perception of insider profit-taking following a potential price run-up
- Risk of negative sentiment if selling continues in coming weeks
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (9 trades, 7d window) | cluster-MDGL-1772840985473 |
Track record
18 reports on MDGL
3 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +10.26% at T+20 after the Jul 30, 2026 report. 3 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry price pending
- Nov 6, 202610d ago SC 13D/A Neutral 3/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
- Nov 6, 202610d ago Insider Buy Bullish 5/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
- Nov 6, 202610d ago Insider Cluster Bullish 5/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
- Nov 5, 202611d ago Institutional Cluster Mixed 3/10 Entry $400.10 to $425.21 Now $423.96 +5.96% ▲ +6.28% +2.99% vs SPY
- Nov 5, 202611d ago Press Release Bullish 5/10 Entry $400.10 to $425.21 Now $423.96 +5.96% ▲ +6.28% +2.99% vs SPY
- Nov 3, 202613d ago 8-K Bullish 7/10 No price data
- Nov 3, 202613d ago Press Release Bullish 6/10 Entry $396.32 to $432.60 Now $423.96 +6.97% ▲ +9.15% +9.74% vs SPY
- Aug 12, 202613w ago 8-K Neutral 3/10 Entry $536.20 to $540.16 Now $423.96 −20.93% ▲ +0.74% +1.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers